News >

Frontline Nivolumab Misses OS Endpoint in Unresectable HCC

Gina Columbus @ginacolumbusonc
Published: Monday, Jun 24, 2019

Bruno Sangro, MD

Bruno Sangro, MD
Nivolumab (Opdivo) did not achieve statistical significance for improved overall survival (OS) compared with sorafenib (Nexavar) as a frontline therapy for patients with unresectable hepatocellular carcinoma (HCC) as per a prespecified analysis, missing the primary endpoint of the phase III CheckMate-459 trial (NCT02576509).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication